Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 2/2011

01-04-2011 | Research Article

The G1 phase arrest and apoptosis by intrinsic pathway induced by valproic acid inhibit proliferation of BGC-823 gastric carcinoma cells

Authors: Xia Zhao, Weihua Yang, Changwen Shi, Wanshan Ma, Jianing Liu, Yunshan Wang, Guosheng Jiang

Published in: Tumor Biology | Issue 2/2011

Login to get access

Abstract

Recent studies have demonstrated that the histone deacetylation level was closely related to the genesis and development of tumors. Thus, activating histone acetyltransferases and/or suppressing histone deacetylases (HDACs) can become an approach for tumor chemotherapy. The histone acetylation regulation often results in the inhibition of cell proliferation, induction of cell apoptosis or differentiation, and cell cycle arrest in G1 phase. It has been demonstrated recently that the traditional anticonvulsant valproic acid was an efficient class I HDAC inhibitor (HDACI); however, its antitumor effect and mechanisms on gastric cancers so far has not been elucidated clearly. In the present study, gastric carcinoma cell lines BGC-823, HGC-27, and SGC-7901 were cultured with valproic acid (VPA) in vitro. The cell morphology was observed by invert microscope, the proliferation was detected by MTT assay, the apoptosis and cell cycle were analyzed by flow cytometry assay with Annexin V/PI and PI, the activities and protein expressions of Caspase 3, Caspase 8, Caspase 9 of BGC-823 cells were detected by spectrophotometry and indirect immunofluorescence technique, respectively. The protein expressions of Cyclin A, Cyclin D1, Cyclin E, P21Waf/cip1 of BGC-823 cells were analyzed by indirect immunofluorescence assay, and messenger ribonucleic acid (mRNA) expressions were detected by RT-PCR assay. The results showed that the proliferation of three kinds of gastric carcinoma cells could be inhibited obviously by VPA, which was related to the apoptosis induction and cell cycle arrest in G1 phase. The intrinsic pathway (cytochrome C pathway) was chiefly involved in the mechanism of apoptosis, which was indicated by activation of Caspase 9 and Caspase 3. The extrinsic pathway was partially involved, with slight activation of Caspase 8. The mechanism underlying its effect on cell cycle arrest in G1 phase induction was due to the upregulation of P21Waf/cip1, Mad1 expression and downregulation of Cyclin A, c-Myc expression.
Literature
1.
Spotswood HT, Turner BM. An increasingly complex code. J Clin Invest. 2002;110:577–82.PubMed
2.
3.
Gray SG, Teh BT. Histone acetylation/deacetylation and cancer: an “open” and “shut” case? Curr Mol Med. 2001;1:401–29.CrossRefPubMed
4.
Marks PA, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nature. 2001;1:194–202.
5.
Satoh A, Toyota M, Itoh F, et al. DNA methylation and histone deacetylation associated with silencing DAP kinase gene expression in colorectal and gastric cancers. Br J Cancer. 2002;86:1817–23.CrossRefPubMed
6.
Vigushin DM, Coombes RC. Targeted histone deacetylase inhibition for cancer therapy. Curr Cancer Drug Targets. 2004;4(2):205–18.CrossRefPubMed
7.
Vigushin DM, Coombes RC. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs. 2002;13:1–13.CrossRefPubMed
8.
Dokmanovic M, Marks PA. Prospects: histone deacetylase inhibitors. J Cell Biochem. 2005;96:293–304.CrossRefPubMed
9.
10.
Aherne GW, Rowlands MG, Stimson L, et al. Assays for the identification and evaluation of histone acetyltransferase inhibitors. Methods. 2002;26:245–53.CrossRef
11.
Urnov FD, Wolffe AP. Chromatin remodeling and transcriptional activation: the cast (in order of appearance). Oncogene. 2001;20:2991–3006.CrossRefPubMed
12.
Somech R, Izraelia S, Simon AJ. Histone deacetylase inhibitors: a new tool to treat cancer. Cancer Treat Rev. 2004;30:461–72.CrossRefPubMed
13.
Yang H, Hoshino K, Sanchez-Gonzalez B, et al. Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid. Leuk Res. 2005;29:739–48.CrossRefPubMed
14.
Cinatl Jr J, Kotchetkov R, Blaheta R, et al. Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE (2)-C cells by valproic acid: enhancement by combination with interferon-alpha. Int J Oncol. 2002;20:97–106.PubMed
15.
Moldenhauer A, Frank RC, Pinilla-Ibarz J, et al. Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins. J Leukoc Biol. 2004;76:623–33.CrossRefPubMed
16.
Kuefer R, Hofer MD, Altug V, et al. Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br J Cancer. 2004;90:535–41.CrossRefPubMed
17.
Known SH, Ahn SH, Kim YK, et al. Apicidin, a histone deacetylase inhibitor, induces apoptosis and FAS/FAS ligand expression in human acute promielocytic leukemia cells. J Biol Chem. 2002;277:2073–80.CrossRef
18.
Aron JL, Parthun MR, Marucci G, et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cell concurrent with activation of Caspase 8-mediated apoptosis and downregulation of c-FLIP protein. Blood. 2003;102:652–8.CrossRefPubMed
19.
Chang DW, Xing Z, Capacio VL, et al. Inter-dimer processing mechanism of procaspase-8 activation. EMBO J. 2003;22:4132–42.CrossRefPubMed
20.
Peart MJ, Tainton KM, Rurefli AA, et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res. 2003;63:4460–71.PubMed
21.
Pei XY, Dai Y, Grant S, et al. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res. 2004;10:3839–52.CrossRefPubMed
22.
Gao LW, Zhang J, Yang WH, Wang B, Wang JW. Glaucocalyxin A induces apoptosis in human leukemia HL-60 cells through mitochondria-mediated death pathway. Toxicol In Vitro. 2010; [Epub ahead of print]
23.
Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related tothe yeast transc riptional regulator Rpd3p. Science. 1996;272:408–11.CrossRefPubMed
24.
Abdul M, Hoosein N. Inhibition by anticonvulsants of prostate-specific antigen and interleukin-6 secretion by human prostate cancer cells. Anticancer Res. 2001;21:2045–8.PubMed
25.
Rocchi P, Tonelli R, Camerin C, et al. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. Oncol Rep. 2005;13:1139–44.PubMed
26.
Vento R, D’Alessandro N, Giuliano M, et al. Induction of apoptosis by arachidonic acid in human retinoblastoma Y79 cells: involvement of oxidative stress. Exp Eye Res. 2000;70:503–17.CrossRefPubMed
27.
Gozzini A, Rovida E, Sbarba PD, et al. Butyrates, as a single drug, induce histone acetylation and granulocytic maturation: possible selectivity on corebinding factor—acute myeloid leukemia blasts. Cancer Res. 2003;63:8955–61.PubMed
28.
Fortunati N, Catalano MG, Arena K, et al. Valproic acid induces the expression of the Na+/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab. 2004;82:1006–9.CrossRef
29.
Luong QT, O’Kelly J, Braunstein GD, et al. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res. 2006;12:5570–7.CrossRefPubMed
30.
Tsou MF, Stearns T. Mechanism limiting centrosome duplication to once per cell cycle. Nature. 2006;442:947–51.CrossRefPubMed
31.
Catalano MG, Fortunati N, Pugliese M, et al. Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab. 2005;90:1383–9.CrossRefPubMed
32.
Zhou Q, He Q, Liang LJ. Expression of p27, Cyclin E and Cyclin A in hepatocellular carcinoma and its clinical significance. World J Gastroenterol. 2003;9:2450–4.PubMed
33.
Macaluso M, Montanari M, Cinti C. Modulation of cell cycle components by epigenetic and genetic events. Semin Oncol. 2005;32:452–7.CrossRefPubMed
34.
Pulukuri SM, Rao JS. Activation of p53/p21Waf1/Cip1 pathway by 5-aza-2′-deoxycytidine inhibits cell proliferation, induces pro-apoptotic genes and mitogen-activated protein kinases in human prostate cancer cells. Int J Oncol. 2005;26:863–71.PubMed
35.
Gozzini A, Santini V. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts. Ann Hematol. 2005;84:54–60.CrossRefPubMed
36.
Kobayashi H, Tan EM, Fleming SE. Acetylation of histones associated with the p21WAF1/CIP1 gene by butyrate is not sufficient for p21WAF1/CIP1 gene transcription in human colorectal adenocarcinoma cells. Int J Cancer. 2004;109:207–13.CrossRefPubMed
37.
Park HY, Kim MK, Moon SI, et al. Cell cycle arrest and apoptotic induction in LNCaP cells by MCS-C2, novel cyclin-dependent kinase inhibitor, through p53/p21WAF1/CIP1 pathway. Cancer Sci. 2006;97:430–6.CrossRefPubMed
38.
Nguyen HQ, Selvakumaran M, Liebermann DA, Hoffman B. Blocking c-Myc and Max expression inhibits proliferation and induces differentiation of normal and leukemic myeloid cells. Oncogene. 1995;11:2439–44.PubMed
39.
Oster SK, Ho CS, Soucie EL, Penn LZ. The Myc oncogene: marvelously complex. Adv Cancer Res. 2002;84:81–154.CrossRefPubMed
40.
Sommer A, Hilfenhaus S, Menkel A, et al. Cell growth inhibition by the Mad/Max complex through recruitment of histone deacetylase activity. Curr Biol. 1997;7:357–65.CrossRefPubMed
41.
Hermeking H, Rago C, Schuhmacher M, et al. Identification of CDK4 as a target of c-MYC. Proc Natl Acad Sci USA. 2000;97:2229–34.CrossRefPubMed
42.
Gustavo L, James D, Rosalie S, Laszlo J, Joseph R. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature. 1997;387:422–6.CrossRef
Metadata
Title
The G1 phase arrest and apoptosis by intrinsic pathway induced by valproic acid inhibit proliferation of BGC-823 gastric carcinoma cells
Authors
Xia Zhao
Weihua Yang
Changwen Shi
Wanshan Ma
Jianing Liu
Yunshan Wang
Guosheng Jiang
Publication date
01-04-2011
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2011
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-010-0126-5

Other articles of this Issue 2/2011

Tumor Biology 2/2011 Go to the issue

Research Article

Oral squamous cell carcinoma versus oral verrucous carcinoma: an approach to cellular proliferation and negative relation to human papillomavirus (HPV)

Research Article

Establishment of three cisplatin-resistant endometrial cancer cell lines using two methods of cisplatin exposure

Research Article

Papillary thyroid carcinoma shows elevated levels of 2-hydroxyglutarate

Research Article

MMP-7 as a prognostic marker in colorectal cancer

Research Article

Genetic mutations of p53 and k-ras in gastric carcinoma patients from Hunan, China

Research Article

Elevated neutrophil to lymphocyte ratio predicts poor prognosis in nasopharyngeal carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits